Is MRK or MTNB more undervalued in 2026?

CirclFi compares Merck & Company, Inc. (MRK) and Matinas Biopharma Holdings, Inc (MTNB) using 13 institutional-grade valuation models. MRK has a Quality of Company score of 9.8/10 while MTNB scores 4.0/10.

Which is a better buy — MRK or MTNB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MRK and MTNB valuations compare?

MRK at $118.72 and MTNB at $0.81 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MRK vs MTNB Valuation Comparison 2026 — Intrinsic Value Analysis

MRK

Pharmaceutical Preparations

Merck & Company, Inc.

Quality

9.8

out of 10

Value Trap

—

Price

$118.72

Last close

Models

13/13

Active

MTNB

Pharmaceutical Preparations

Matinas Biopharma Holdings, Inc

Quality

4.0

out of 10

Value Trap

LOW

Price

$0.81

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	MRK Fair Value	MRK Upside	MTNB Fair Value	MTNB Upside
Bayesian DCF	Intrinsic	$67.39	-43.2%	$0.42	-48.6%
Earnings Power Value	Intrinsic	$17.85	-85.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$10.61	-91.1%	$3.08	+279.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MRK vs MTNB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MRK vs MTNB — Which Stock Is More Undervalued?

MRK scores higher with a 9.8/10 quality rating vs MTNB's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Merck & Company, Inc. (MRK) and Matinas Biopharma Holdings, Inc (MTNB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MRK currently trades at $118.72 with a QOC of 9.8/10, while MTNB trades at $0.81 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).